Recurrent Viral Liver Disease (Hepatitis B and C) after Liver Transplantation

Archives of Medical Research

Volumn 38, Issue 6, 2007, Pages 691-701

  Olivera Martínez, Marco Antonio ^a   Gallegos Orozco, Juan F ^b  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b MAYO CLINIC   (United States)

Author keywords

Hepatitis B; Hepatitis C; Liver reinfection; Liver transplant

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AMANTADINE; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; ENTECAVIR; FOLIC ACID; HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; HEPATITIS C ANTIBODY; INTERFERON; LAMIVUDINE; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE; NUCLEOSIDE ANALOG; OKT 3; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT VACCINE; RIBAVIRIN; TACROLIMUS; TENOFOVIR;

ADD ON THERAPY; ADJUVANT THERAPY; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; NEPHROTOXICITY; ORGAN DONOR; RECURRENT DISEASE; REINFECTION; REVIEW; RISK FACTOR; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS;

ANTIVIRAL AGENTS; CYCLOSPORINE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; NUCLEIC ACID SYNTHESIS INHIBITORS; RECURRENCE; RISK FACTORS;

EID: 34347214442     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2006.09.003     Document Type: Review

References (105)

1. Wang Z.X., Ding G.S., Fu H., Zhang J.J., Chen X.S., Guo W.Y., et al. Prevention of hepatitis B virus infection after orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int 3 (2004) 345
2. Terrault N., Roche B., and Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 7 (2005) 716-732
3. Todo S., Demetris A.J., Van Thiel D., Tepperman L., Fung J.J., and Starzl T.E. Orthotopic liver transplantation for patients with hepatitis B virus related liver disease. Hepatology 13 (1991) 619-626
4. Shouval D., and Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft re-infection following liver transplantation: a concise review. Hepatology 32 (2000) 1189-1195
5. Vierling J.M. Management of hepatitis B infection in liver transplantation. Int J Med Sci 2 (2005) 41-49
6. McGory R.W., Ishitani M., Oliveira W., Stevenson W., McCollough C., Dickson R., Caldwell S., et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 61 (1996) 1358-1364
7. Rosen H.R., and Martin P. Liver transplantation in patients with chronic hepatitis B and C. In: Maddrey W.C., Schiff E.R., and Sorrell M.F. (Eds). Transplantation of the Liver (2001), Lippincott Williams & Wilkins, Philadelphia 327-341
8. Samuel D., Muller R., Alexander G., Fassati L., Ducot B., Benhamou J.P., et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329 (1993) 1842-1847
9. Naumann U., Protzer-Knolle U., Berg T., Leder K., Lobeck H., Bechstein W.O., et al. A pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti-hepatitis B virus surface antigen immunoprophylaxis. Hepatology 2 (1997) 478-484
10. Seehofer D., and Berg T. Prevention of hepatitis B recurrence after liver transplantation. Transplantation 80 (2005) S120-S124
11. Seehofer D., Rayes N., Naumann U., Neuhaus R., Muller A.R., Tullius S.G., et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 78 (2001) 1381-1385
12. Eehofer D., Rayes N., Naumann U., Neuhaus R., Muller A.R., Tullis S.G., et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 72 (2001) 1381-1385
13. Kim W.R., Poterucha J.J., Kremers W.K., Ishitani M.B., and Dickson E.R. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 10 (2004) 968-974
14. Mutimer D., Pillay D., Dragon E., Tang H., Ahmed M., O'Donnell K., et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 30 (1999) 715-721
15. Seehofer D., Rayes N., Berg T., Neuhaus R., Muller A.R., Hopf U., et al. Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. Transplant Int 13 (2000) 290-296
16. Grellier L., Mutimer D., Ahmed M., Brown D., Burroughs A.K., Rolles K., et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348 (1996) 1212-1215
17. Mutimer D., Pillay D., Shields P., Cane P., Rattcliffe D., Martin B., et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 46 (2000) 107-113
18. Perrillo R.P., Wright T., Rakela J., Levy G., Schiff E., Gish R., et al. A multi-center United States-Canadian trial to assess lamividine monotherapy before and after transplantation for chronic hepatitis B. Hepatology 33 (2001) 424-432
19. Nath D.S., Kalis A., Nelson S., Payne W.D., Lake J.R., and Humar A. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant 20 (2006) 206-210
20. Angus P.W., McCaughan G.W., Gane E.J., Crawford D.H., and Harley M.H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post-transplantation hepatitis B. Liver Transpl 6 (2000) 429-433
21. Lu M.Q., Cai C.J., Zhao H., Yang Y., and Chen G.H. Prevention and treatment of hepatitis B virus reinfection after liver transplantation. Zhonghua Wai Ke Za Zhi 44 (2006) 742-744
22. Zheng S., Chen Y., Liang T., Lu A., Wang W., Shen Y., et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immune globulin prophylaxis. Liver Transpl 12 (2006) 253-258
23. Schiff E.R., Hadziyannis S., Neuhaus P., Terrault N., Colombo M., Tillmann H.L., et al. Adefovir dipivoxil therapy for lamivudine resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 38 (2003) 1419-1427
24. Angus P., Vaughan R., Xiong S., Yang H., Delaney W., Gibbs C., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 (2003) 292-297
25. Bárcena R., Del Campo S., Moraleda G., Casanovas T., Prieto M., Buti M., et al. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine resistant Hepatitis B virus. Transplant Proc 37 (2005) 3960-3962
26. Lo C.M., Liu C.L., Lau G.K., Chan S.C., Ng I.O., and Fan S.T. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transplant 11 (2005) 807-813
27. Quan D.J., and Peters M.G. Antiviral therapy: nucleoside and nucleotide analogues. Clin Liver Dis 8 (2004) 371-385
28. Honkoop P., and de Man R.A. Entecavir: A potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs 12 (2003) 683-688
29. Shakil A.O., Angus P., Gerken G., et al. Entecavir reduces viral load in liver transplant patients who have failed prophylaxis or treatment for hepatitis B. Hepatology 34 (2001) 619A
30. Schreibam I.R., and Schiff E.R. Prevention and treatment of recurrent hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann Clin Microbiol Antimicrob 5 (2006) 8. http://www.ann-clinmicrob.com/content/5/1/8 10.1186/1476-0711-5-8
31. Neff G.W., Nery J., Lau D.T., O'Brien C.B., Duncan R., Shire N.J., et al. Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmco-Therapy 38 (2004) 1999-2004
32. Bienzle U., Günther M., Neuhaus R., Vandepapeliere P., Vollmar J., Lun A., and Neuhaus P. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 38 (2003) 811-819
33. Sánchez-Fueyo A., Rimola A., Grande L., Costa J., Mas A., Navasa M., et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 31 (2000) 496-501
34. Dahmen U., Dirsch O., Li J., Fiedle M., Lu M., Rispeter K., et al. Adoptive transfer of immunity: a new strategy to interfere with severe hepatitis virus re-infection after woodchuck liver transplantation. Transplantation 77 (2004) 965-972
35. Brown R.S. Hepatitis C and liver transplantation. Nature 436 (2005) 973-978
36. Terrault N.A. Treatment of recurrent hepatitis C in liver transplant recipients. Clin Gastroenterol Hepatol 3 Suppl 2 (2005) S125-S131
37. Rodriguez-Luna H., and Vargas H.E. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl 11 (2005) 479-489
38. Sharma P., and Lok A. Viral hepatitis and liver transplantation. Semin Liver Dis 26 (2006) 285-297
39. Pelletier S.J., Iezzoni J.C., Crabtree T.D., Hahn Y.S., Sawyer R.G., and Pruett T.L. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 6 (2000) 44-53
40. Pelletier S.J., Raymond D.P., Crabtree T.D., Berg C.L., Iezzoni J.C., Hahn Y.S., et al. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. Hepatology 32 (2000) 418-426
41. Berenguer M., Ferrell L., Watson J., Prieto M., Kim M., Rayon M., et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 32 (2000) 673-684
42. Firpi R.J., Abdelmalek M.F., Soldevila-Pico C., Cabrera R., Shuster J.J., Theriaque D., et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 10 (2004) 1240-1247
43. Saab S., Niho H., Comulada S., Hiatt J., Durazo F., Han S., et al. Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis. Liver Int 25 (2005) 940-945
44. Forman L.M., Lewis J.D., Berlin J.A., Feldman H.I., and Lucey M.R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122 (2002) 889-896
45. Wiesner R.H., Sorrell M., and Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 9 (2003) S1-S9
46. Neumann U.P., Berg T., Bahra M., Seehofer D., Langrehr J.M., Neuhaus R., et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 41 (2004) 830-836
47. Berenguer M., Prieto M., San Juan F., Rayon J.M., Martinez F., Carrasco D., et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 36 (2002) 202-210
48. Wali M., Harrison R.F., Gow P.J., and Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 51 (2002) 248-252
49. Charlton M. Recurrence of hepatitis C infection: where are we now?. Liver Transpl 11 Suppl 2 (2005) S57-S62
50. Samonakis D.N., Triantos C.K., Thalheimer U., Quaglia A., Leandro G., Teixeira R., et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 11 (2005) 386-395
51. Belli L.S., Burra P., Poli F., Battista Alberti A., Silini E., Zavaglia C., et al. HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation. Gastroenterology 130 (2006) 695-702
52. Kimball P., and Stravitz T. DR antigens influence graft outcome and HCV recurrence after liver transplantation. Transplant Proc 37 (2005) 1099-1100
53. Ben-Ari Z., Tambur A.R., Pappo O., Sulkes J., Pravica V., Hutchinson I., et al. Platelet-derived growth factor gene polymorphism in recurrent hepatitis C infection after liver transplantation. Transplantation 81 (2006) 392-397
54. Watt K.D., Lyden E.R., Gulizia J.M., and McCashland T.M. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl 12 (2006) 134-139
55. Gawrieh S., Papouchado B.G., Burgart L.J., Kobayashi S., Charlton M.R., and Gores G.J. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl 11 (2005) 1207-1213
56. Nelson D.R., Soldevila-Pico C., Reed A., Abdelmalek M.F., Hemming A.W., Van der Werf W.J., et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 7 (2001) 1064-1070
57. Chopra K.B., Demetris A.J., Blakolmer K., Dvorchik I., Laskus T., Wang L.F., et al. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 76 (2003) 1487-1491
58. Burak K.W., Kremers W.K., Batts K.P., Wiesner R.H., Rosen C.B., Razonable R.R., et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 8 (2002) 362-369
59. Neff G.W., delaGarza J., Shire N., Nishida S., O'Brien C.B., Safdar K., et al. The long-term effects of immune suppression on liver transplant recipients with recurrent hepatitis C viral infection. Transplant Proc 36 (2004) 3065-3067
60. Bahr M.J., Beckermann J.G., Rifai K., Gehrmann L., Rosenau J., Klempnauer J., et al. Retrospective analysis of the impact of immunosuppression on the course of recurrent hepatitis C after liver transplantation. Transplant Proc 37 (2005) 1703-1704
61. Hilgard P., Kahraman A., Lehmann N., Seltmann C., Beckebaum S., Ross R.S., et al. Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: effects on virus replication and recurrent hepatitis. World J Gastroenterol 12 (2006) 697-702
62. Martin P., Busuttil R.W., Goldstein R.M., Crippin J.S., Klintmalm G.B., Fitzsimmons W.E., et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 10 (2004) 1258-1262
63. Inoue K., and Yoshiba M. Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease. Transplant Proc 37 (2005) 1233-1234
64. Firpi R.J., Zhu H., Morelli G., Abdelmalek M.F., Soldevila-Pico C., Machicao V.I., et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 12 (2006) 51-57
65. Nakagawa M., Sakamoto N., Enomoto N., Tanabe Y., Kanazawa N., Koyama T., et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 313 (2004) 42-47
66. Wiesner R.H., Shorr J.S., Steffen B.J., Chu A.H., Gordon R.D., and Lake J.R. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 11 (2005) 750-759
67. Jain A., Kashyap R., Demetris A.J., Eghstesad B., Pokharna R., and Fung J.J. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 8 (2002) 40-46
68. Bahra M., Neumann U.I., Jacob D., Puhl G., Klupp J., Langrehr J.M., et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. Am J Transplant 5 (2005) 406-411
69. Filipponi F., Callea F., Salizzoni M., Grazi G.L., Fassati L.R., Rossi M., et al. Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 78 (2004) 1488-1495
70. Pelletier S.J., Vanderwall K., Debroy M.A., Englesbe M.J., Sung R.S., Magee J.C., et al. Preliminary analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation. Transplant Proc 37 (2005) 1214-1216
71. Kato T., Yoshida H., Sadfar K., Martinez E., Nishida S., Moon J., et al. Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study. Transplant Proc 37 (2005) 1217-1219
72. Nair S., Loss G.E., Cohen A.J., and Eason J.D. Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection. Transplantation 81 (2006) 620-622
73. Llado L., Xiol X., Figueras J., Ramos E., Memba R., Serrano T., et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J Hepatol 44 (2006) 710-716
74. Tisone G., Orlando G., Cardillo A., Palmieri G., Manzia T.M., Baiocchi L., et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 44 (2006) 702-709
75. Berenguer M., Aguilera V., Prieto M., San Juan F., Rayon J.M., Benlloch S., et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 44 (2006) 717-722
76. Forns X., Garcia-Retortillo M., Serrano T., Feliu A., Suarez F., de la Mata M., et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 39 (2003) 389-396
77. Everson G.T., Trotter J., Forman L., Kugelmas M., Halprin A., Fey B., et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 42 (2005) 255-262
78. Moreno Planas J.M., Rubio Gonzalez E., Boullosa Grana E., Fernandez Ruiz M., Jimenez Garrido M., Lucena de la Poza J.L., et al. Effectiveness of pegylated interferon and ribavirin in patients with liver HCV cirrhosis. Transplant Proc 37 (2005) 1482-1483
79. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
80. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
81. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
82. Davis G.L., Nelson D.R., Terrault N., Pruett T.L., Schiano T.D., Fletcher C.V., et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 11 (2005) 941-949
83. Eren R., Landstein D., Terkieltaub D., Nussbaum O., Zauberman A., Ben-Porath J., et al. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 80 (2006) 2654-2664
84. Mazzaferro V., Tagger A., Schiavo M., Regalia E., Pulvirenti A., Ribero M.L., et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 33 (2001) 1355-1357
85. Castells L., Vargas V., Allende H., Bilbao I., Luis Lazaro J., Margarit C., et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 43 (2005) 53-59
86. Castedal M., Felldin M., Backman L., Olausson M., and Friman S. Preemptive therapy with pegylated interferon alpha-2b and ribavirin after liver transplantation for hepatitis C cirrhosis. Transplant Proc 37 (2005) 3313-3314
87. Chalasani N., Manzarbeitia C., Ferenci P., Vogel W., Fontana R.J., Voigt M., et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 41 (2005) 289-298
88. Rodriguez-Luna H., Khatib A., Sharma P., De Petris G., Williams J.W., Ortiz J., et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 77 (2004) 190-194
89. Neff G.W., Montalbano M., O'Brien C.B., Nishida S., Safdar K., Bejarano P.A., et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 78 (2004) 1303-1307
90. Bizollon T., Adham M., Pradat P., Chevallier M., Ducerf C., Baulieux J., et al. Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C. Transplantation 79 (2005) 325-329
91. Moreno Planas J.M., Rubio Gonzalez E., Boullosa Grana E., Garrido Botella A., Barrios Peinado C., Lucena Poza J.L., et al. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transplant Proc 37 (2005) 2207-2208
92. Babatin M., Schindel L., and Burak K.W. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: from a Canadian experience to recommendations for therapy. Can J Gastroenterol 19 (2005) 359-365
93. Yedibela S., Schuppan D., Muller V., Schellerer V., Tannapfel A., Hohenberger W., et al. Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation. Liver Int 25 (2005) 717-722
94. Oton E., Barcena R., Garcia-Garzon S., Moreno-Zamora A., Moreno A., Garcia-Gonzalez M., et al. Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients. Transplant Proc 37 (2005) 3963-3964
95. Mukherjee S. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 37 (2005) 4403-4405
96. Biselli M., Andreone P., Gramenzi A., Lorenzini S., Loggi E., Bonvicini F., et al. Pegylated interferon plus ribavirin for recurrent hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. Dig Liver Dis 38 (2006) 27-32
97. Heydtmann M., Freshwater D., Dudley T., Lai V., Palmer S., Hubscher S., et al. Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation. Am J Transplant 6 (2006) 825-833
98. Bizollon T., Pradat P., Mabrut J.Y., Chevallier M., Adham M., Radenne S., et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 5 (2005) 1909-1913
99. Schiano T.D., Gutierrez J.A., Walewski J.L., Fiel M.I., Cheng B., Bodenheimer Jr. H., et al. Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology 42 (2005) 1420-1428
100. Sugawara Y., Makuuchi M., Matsui Y., Kishi Y., Akamatsu N., Kaneko J., et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 78 (2004) 1308-1311
101. Ghobrial R.M. Retransplantation for recurrent hepatitis C. Liver Transpl 8 Suppl 1 (2002) S38-S43
102. Neff G.W., O'Brien C.B., Nery J., Shire N.J., Nishida S., de la Garza J., et al. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl 10 (2004) 1497-1503
103. Burton Jr. J.R., and Rosen H.R. Liver retransplantation for hepatitis C virus recurrence: a survey of liver transplant programs in the United States. Clin Gastroenterol Hepatol 3 (2005) 700-704
104. Rosen H.R., and Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 66 (1998) 1612-1616
105. Carmiel-Haggai M., Fiel M.I., Gaddipati H.C., Abittan C., Hossain S., Roayaie S., et al. Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl 11 (2005) 1567-1573